Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in Children With Noonan Syndrome
NCT06668805Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 2, randomised trial of vosoritide in Noonan syndrome (3 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: Annualized Growth Velocity at 6 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on NCT06668805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668805.